Population pharmacokinetic analysis of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase), in Parkinson ’s Disease patients and healthy volunteers

Background: BIA 28-6156 is an allosteric activator of beta-glucocerebrosidase (GCase) and is being developed by BIAL - Portela& Ca, S.A. as a potential treatment for Parkinson ’s Disease (PD) patients who have PD-risk associated variant in the GBA1 gene (GBA-PD).
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research